Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by Credit Suisse Group

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “buy” rating restated by analysts at Credit Suisse Group in a report released on Monday. They currently have a $485.00 target price on the biopharmaceutical company’s stock. Credit Suisse Group’s price target points to a potential upside of 2.87% from the company’s previous close.

Several other analysts also recently commented on REGN. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 15th. Robert W. Baird downgraded Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price on the stock. in a research note on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $472.00 target price (up from $469.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 target price on the stock in a research note on Wednesday, August 9th. Finally, Leerink Swann reiterated an “outperform” rating and set a $580.00 target price (up from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. Regeneron Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $496.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 5.5012% on Monday, reaching $445.5525. The company’s stock had a trading volume of 1,319,558 shares. The stock has a market cap of $47.24 billion, a PE ratio of 44.6983 and a beta of 1.65. The company’s 50 day moving average price is $482.49 and its 200-day moving average price is $443.81. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same period last year, the business posted $2.82 EPS. The company’s revenue was up 21.2% compared to the same quarter last year. On average, equities analysts expect that Regeneron Pharmaceuticals will post $14.90 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by Credit Suisse Group” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/09/11/regeneron-pharmaceuticals-inc-regn-rating-reiterated-by-credit-suisse-group.html.

In other news, major shareholder Sanofi bought 166,415 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, August 24th. The shares were purchased at an average cost of $480.93 per share, with a total value of $80,033,965.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Neil Stahl sold 8,306 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the sale, the executive vice president now directly owns 43,950 shares in the company, valued at $23,405,572.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 129,257 shares of company stock worth $61,745,394. Insiders own 10.40% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Fieldpoint Private Securities LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $130,000. Sterling Investment Advisors Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares during the last quarter. FNY Managed Accounts LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth about $140,000. FNY Partners Fund LP increased its holdings in shares of Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the last quarter. Finally, Alpha Windward LLC increased its holdings in shares of Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 1 shares during the last quarter. 67.96% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply